China Pharma Holdings (CPHI) Land & Improvements (2014 - 2023)
China Pharma Holdings (CPHI) posted Land & Improvements of $389808.0 for Q2 2023, down 4.9% on a QoQ basis from $409895.0 in Q1 2023, and down 7.12% year-over-year from $419685.0 in Q2 2022.
China Pharma Holdings (CPHI) Land & Improvements (2014 - 2023) Analysis & Trends
China Pharma Holdings' Land & Improvements history runs 10 years deep, the most recent figure standing at $389808.0 for Q2 2023.
- Quarterly Land & Improvements fell 7.12% year-over-year to $389808.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $389808.0 (down 7.12% YoY) and the FY2022 annual result came in at $404427.0, down 8.46% from the prior year.
- Land & Improvements was $389808.0 for Q2 2023 at China Pharma Holdings, down from $409895.0 in the prior quarter.
- Across five years, Land & Improvements topped out at $443697.0 in Q1 2022 and bottomed at $389808.0 in Q2 2023.
- A 5-year average of $416443.1 and a median of $413603.0 in 2020 frame the typical range for Land & Improvements.
- Annual changes were most pronounced in 2021 — Land & Improvements increased 9.59% — and 2022, when it decreased 8.65%.
- China Pharma Holdings' Land & Improvements stood at $403755.0 in 2019, then advanced by 6.92% to $431681.0 in 2020, then climbed by 2.34% to $441783.0 in 2021, then retreated by 8.46% to $404427.0 in 2022, then dropped by 3.61% to $389808.0 in 2023.
- Business Quant data shows CPHI's Land & Improvements at $389808.0 in Q2 2023, $409895.0 in Q1 2023, and $404427.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 389,808.00 |
| Mar 31, 2023 | 409,895.00 |
| Dec 31, 2022 | 404,427.00 |
| Sep 30, 2022 | 396,726.00 |
| Jun 30, 2022 | 419,685.00 |
| Mar 31, 2022 | 443,697.00 |
| Dec 31, 2021 | 441,783.00 |
| Sep 30, 2021 | 434,310.00 |
| Jun 30, 2021 | 436,011.00 |
| Dec 31, 2020 | 431,681.00 |
| Sep 30, 2020 | 413,603.00 |
| Jun 30, 2020 | 397,864.00 |
| Mar 31, 2020 | 428,633.00 |
| Dec 31, 2019 | 403,755.00 |
| Sep 30, 2019 | 398,235.00 |
| Jun 30, 2019 | 409,716.00 |
| Mar 31, 2019 | 419,703.00 |
| Dec 31, 2018 | 409,612.00 |
| Sep 30, 2018 | 410,203.00 |
| Jun 30, 2018 | 425,541.00 |